Abstracts from the 7th international forum on mood and anxiety disorders

References

• Angst J., Angst F., Gerber-Werder R., Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res 2005; 9: 279–300
   PubMedGoogle Scholar
• Angst J., Battegay R., Poeldinger W. Zur Methodik der statistischen Bearbeitung des Therapieverlaufs depressiver Krankheitsbilder. Methods Inf Med 1964; 3: 54–56
   PubMed Web of Science ®Google Scholar
• Angst J., et al. Arch Suic Res 2005; 9: 279–300
   PubMedGoogle Scholar
• Baldessarini RJ., et al. Bipol. Disord 2006; 8: 625–639
   PubMed Web of Science ®Google Scholar
• Rihmer Z. Curr Opin Psychiat 2007; 20: 17–22
   PubMed Web of Science ®Google Scholar
• Pjrek E, Winkler D, Stastny J, Praschak-Rieder N, Willeit M, Kasper S. Escitalopram in seasonal affective disorder: results of an open trial. Pharmacopsychiatry 2007; 40: 20–24
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Andersen HF:Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006; Sep;21(5)297–309
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF. Lam RW: Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci. 2006; Mar;31(2)122–31
   PubMed Web of Science ®Google Scholar
• Papakostas GI Thase ME Fava M Craig Nelson J Shelton RC Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents. Biol Psychiatry. (In Press)
   Google Scholar
• Papakostas GI. Current limitations of antidepressant monotherapy: tolerability. J Clin Psychiatry. 2007; 68(s10)11–18
   PubMedGoogle Scholar
• Chamberlain SR, Fineberg NA, Blackwell AD, Robbins TW, Sahakian BJ. Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am J Psychiatry. 2006; Jul;163(7)1282–4
   PubMed Web of Science ®Google Scholar
• Chamberlain SR, Fineberg NA, Blackwell A, Robbins TW, Sahakian BJ. Impaired cognitive function and motor inhibition in first degree relatives of OCD patients: on the trail of endophenotypes. Am J Psychiatry 2007; 164: 335–338
   PubMed Web of Science ®Google Scholar
• Menzies L Achard S Chamberlain SR Fineberg N Chen CH Del Campo N Sahakian BJ Robbins TW Bullmore E Neurocognitive endophenotypes of obsessive-compulsive disorder. Brain. 2007 Sep 13; [Epub ahead of print].
   Google Scholar
• Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol. 2005; 15(4)445–52
   PubMed Web of Science ®Google Scholar
• Bech P. Dose-response Relationship of Pregabalin in Patients with Generalized Anxiety Disorder. A Pooled Analysis of Four Placebo-controlled Trials. Pharmacopsychiatry. 2007; 40(4)163–8
   PubMed Web of Science ®Google Scholar
• Corruble E, Guelfi J-D. Pain complaints in depressed inpatients. Psychopathology 2000; 33: 307–309
   PubMed Web of Science ®Google Scholar
• Krimayer LJ, et al. Somatization and the recognition of depression and anxiety in primary care. Am. J. Psychiatry 1993; 150: 734–741
   PubMed Web of Science ®Google Scholar
• Fava M. The role of the serotoninergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J. Clin. Psychiatry 2003; 64(suppl. 13)26–29
   PubMed Web of Science ®Google Scholar
• Stahl M, Briley M. Understanding pain and depression. Hum. Psychopharmacol. Clin. Exp. 2004; 19: S9–S13
   PubMed Web of Science ®Google Scholar
• Baldwin DS Polkinghorn C Int J Neuropsychopharmacol 2005; 8: 293–302.
   PubMed Web of Science ®Google Scholar
• Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health: Research agenda for the next 2 decades. Arch Gen Psychiatry 1999; 56: 848–853
   PubMed Web of Science ®Google Scholar
• Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155: 1521–1528
   PubMed Web of Science ®Google Scholar
• Zarate CA, Jr, Baldessarini RJ, Siegel AJ, et al. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997; 58: 311–317
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31: 122–131
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 1270–1278
   PubMed Web of Science ®Google Scholar
• Karow A., Lambert M. Polypharmacy in treatment with psychotropic drugs: the underestimated phenomenon. Current Opinion in Psychiatry. 2003; 16(6)713–718, November 2003
   Web of Science ®Google Scholar
• Hale AS. ABC of mental health: Anxiety. BMJ 1997;314:1886.
   Google Scholar
• Pathare SR, Paton C. ABC of mental health: Psychotropic drug treatment. BMJ 1997; 315: 661–664
   PubMedGoogle Scholar
• National Institute for Health and Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. Technology Appraisal 77. National Institute for Health and Clinical Excellence, London April;2004
   Google Scholar
• Grohmann R., Engel R.R., Rüther E., Hippius H. The AMSP Drug Safety Program: Methods and Global Results. Pharmacopsych 37 Suppl 2004; 1: S4–S11
   Google Scholar
• Levitt AJ, Boyle MH, Joffe RT, Baumal Z. Estimated prevalence of the seasonal subtype of major depression in a Canadian community sample. Can J Psychiatry 2000; 45: 650–654
   PubMed Web of Science ®Google Scholar
• Pendse BP, Ojehagen A, Engstrom G, Traskman-Bendz L. Social characteristics of seasonal affective disorder patients: comparison with suicide attempters with non-seasonal major depression and other mood disorder patients. Eur Psychiatry 2003; 18: 36–39
   PubMed Web of Science ®Google Scholar
• Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C. Clin Drug Investig 2007; 27: 481–492
   PubMed Web of Science ®Google Scholar
• Wade A, Gembert K, Florea I. Curr Med Res Opin 2007; 23: 1605–1614
   PubMed Web of Science ®Google Scholar
• Winkler D, Pjrek E, Iwaki R, Kasper S. The treatment of seasonal affective disorder. Expert Rev Neurother 2006; 6: 1039–1048
   PubMedGoogle Scholar
• Pjrek E, Winkler D, Stastny J, Konstantinidis A, Heiden A, Kasper S. Bright light therapy in seasonal affective disorder – does it suffice?. Eur Neuropsychopharmacol 2004; 14: 347–351
   PubMed Web of Science ®Google Scholar